Sandra Voorend-van Bergen1, Anja A Vaessen-Verberne2, Hein J Brackel3, Anneke M Landstra4, Norbert J van den Berg5, Wim C Hop6, Johan C de Jongste1, Peter J Merkus7, Mariëlle W Pijnenburg1. 1. Department of Paediatrics, Division Paediatric Respiratory Medicine, Erasmus University Medical Centre-Sophia Children's Hospital, Rotterdam, the Netherlands. 2. Department of Paediatrics, Amphia Hospital, Breda, the Netherlands. 3. Department of Paediatrics, Catharina Hospital, Eindhoven, the Netherlands. 4. Department of Paediatrics, Rijnstate Hospital, Arnhem, the Netherlands. 5. Department of Paediatrics, Flevo Hospital-De Kinderkliniek, Almere, the Netherlands. 6. Department of Biostatistics, Erasmus University Medical Centre, Rotterdam, the Netherlands. 7. Department of Paediatric Pulmonology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Abstract
BACKGROUND: Asthma guidelines recommend monitoring of asthma control. However, in a substantial proportion of children, asthma is poorly controlled and the best monitoring strategy is not known. OBJECTIVES: We studied two monitoring strategies for their ability to improve asthma outcomes in comparison with standard care (SC): web-based monthly monitoring with the (Childhood) Asthma Control Test (ACT or C-ACT) and 4-monthly monitoring of FENO. METHODS: In this randomised controlled, partly blinded, parallel group multicentre trial with a 1-year follow-up, children aged 4-18 with a doctor's diagnosis of asthma treated in seven hospitals were randomised to one of the three groups. In the web group, treatment was adapted according to ACT obtained via a website at 1-month intervals; in the FENO group according to ACT and FENO, and in the SC group according to the ACT at 4-monthly visits. The primary endpoint was the change from baseline in the proportion of symptom-free days (SFD). RESULTS:Two-hundred and eighty children (mean age 10.4 years, 66% boys) were included; 268 completed the study. Mean changes from baseline in SFD were similar between the groups: -2.1% (web group, n=90), +8.9% (FENOgroup, n=91) versus 0.15% (SC, n=87), p=0.15 and p=0.78. Daily dose of inhaled corticosteroids (ICS) decreased more in the web-based group compared with both other groups (-200 μg/day, p<0.01), while ACT and SFD remained similar. CONCLUSIONS: The change from baseline in SFD did not differ between monitoring strategies. With web-based ACT monitoring, ICS could be reduced substantially while control was maintained. TRIAL REGISTRATION NUMBER: NTR 1995. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
BACKGROUND:Asthma guidelines recommend monitoring of asthma control. However, in a substantial proportion of children, asthma is poorly controlled and the best monitoring strategy is not known. OBJECTIVES: We studied two monitoring strategies for their ability to improve asthma outcomes in comparison with standard care (SC): web-based monthly monitoring with the (Childhood) Asthma Control Test (ACT or C-ACT) and 4-monthly monitoring of FENO. METHODS: In this randomised controlled, partly blinded, parallel group multicentre trial with a 1-year follow-up, children aged 4-18 with a doctor's diagnosis of asthma treated in seven hospitals were randomised to one of the three groups. In the web group, treatment was adapted according to ACT obtained via a website at 1-month intervals; in the FENO group according to ACT and FENO, and in the SC group according to the ACT at 4-monthly visits. The primary endpoint was the change from baseline in the proportion of symptom-free days (SFD). RESULTS: Two-hundred and eighty children (mean age 10.4 years, 66% boys) were included; 268 completed the study. Mean changes from baseline in SFD were similar between the groups: -2.1% (web group, n=90), +8.9% (FENO group, n=91) versus 0.15% (SC, n=87), p=0.15 and p=0.78. Daily dose of inhaled corticosteroids (ICS) decreased more in the web-based group compared with both other groups (-200 μg/day, p<0.01), while ACT and SFD remained similar. CONCLUSIONS: The change from baseline in SFD did not differ between monitoring strategies. With web-based ACT monitoring, ICS could be reduced substantially while control was maintained. TRIAL REGISTRATION NUMBER: NTR 1995. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Nicholas R Jones; Kay Wang; Yaling Yang; Carl Heneghan; Christopher P Price; Ann Van den Bruel; Annette Plüddemann Journal: Br J Gen Pract Date: 2017-11 Impact factor: 5.386
Authors: Amy Chan; Anna De Simoni; Vari Wileman; Lois Holliday; Chris J Newby; Claudia Chisari; Sana Ali; Natalee Zhu; Prathima Padakanti; Vasita Pinprachanan; Victoria Ting; Chris J Griffiths Journal: Cochrane Database Syst Rev Date: 2022-06-13
Authors: Shona Fielding; Marielle Pijnenburg; Johan C de Jongste; Katharine C Pike; Graham Roberts; Helen Petsky; Anne B Chang; Maria Fritsch; Thomas Frischer; Stanley Szefler; Peter Gergen; Francoise Vermeulen; Robin Vael; Steve Turner Journal: Chest Date: 2018-10-22 Impact factor: 9.410
Authors: Michelle M Cloutier; Alan P Baptist; Kathryn V Blake; Edward G Brooks; Tyra Bryant-Stephens; Emily DiMango; Anne E Dixon; Kurtis S Elward; Tina Hartert; Jerry A Krishnan; Robert F Lemanske; Daniel R Ouellette; Wilson D Pace; Michael Schatz; Neil S Skolnik; James W Stout; Stephen J Teach; Craig A Umscheid; Colin G Walsh Journal: J Allergy Clin Immunol Date: 2020-12 Impact factor: 10.793
Authors: Victoria L Tiase; Sarah E Wawrzynski; Katherine A Sward; Guilherme Del Fiol; Catherine Staes; Charlene Weir; Mollie R Cummins Journal: Appl Clin Inform Date: 2021-07-21 Impact factor: 2.342